rac-3-methoxy-17-methyl-morphinane; hydrobromide | 72017-39-1

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: rac-3-methoxy-17-methyl-morphinane; hydrobromide
• 英文别名: rac-3-Methoxy-17-methyl-morphinan; Hydrobromid；3-Methoxy-17-methylmorphinan hydrobromide hydrate；(1R,9R,10R)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene;hydrate;hydrobromide
• CAS: 72017-39-1
• 化学式: BrH*C₁₈H₂₅NO*H₂O
• 分子量: 370.33
• InChiKey: STTADZBLEUMJRG-AZVNSBTFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.14
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  13.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  rac-3-methoxy-17-methyl-morphinane; hydrobromide 在 1-甲氧基金刚烷 、 lithium 、 乙二胺 作用下， 以 四氢呋喃 、 叔丁醇 为溶剂， 反应 0.08h， 以54%的产率得到(4bS,9S)-3-methoxy-11-methyl-4,5,6,7,8,8a,9,10-octahydro-1H-9,4b-(epiminoethano)phenanthrene
  参考文献：
  名称：

  Non-Cryogenic, Ammonia-Free Reduction of Aryl Compounds

  摘要：

  在化合物中减少芳香环或环状烯丙基醚的方法包括准备反应混合物，其中包括含有芳香基团或环状烯丙基醚基团的化合物，一种碱金属，以及乙二胺、二乙二胺、三乙二胺或其组合物之一，在醚溶剂中；并将反应混合物在-20°C至30°C的温度下反应一段足够时间，以将芳香基团中的双键还原为单键，或减少环状烯丙基醚基团。

  公开号：

  US20220089508A1

文献信息

• Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
  申请人：Billstein Anthony Stephan

  公开号：US20080090878A1

  公开（公告）日：2008-04-17

  The present invention relates to a combination of a first agent including either a 5-HT 4 receptor agonist or antagonist or a 5-HT 3 receptor antagonist and a co-agent and pharmaceutical compositions and formulations containing the combination. The present invention also relates to a method of treating a gastrointestinal and abdominal viscera disorder by administering the pharmaceutical compositions to a patient. The pharmaceutical compositions may also be employed as laxatives, to prepare a patient for colonoscopy and to regulate and stabilize enterochromaffin cell secretory, pain and motility mechanisms, afferent fiber activity and GI and lower abdominal smooth muscle cells. The dosage is preferably oral and administration is preferably once or twice a day. The preferred first agent is tegaserod.
• MODIFIED RELEASE LIQUID PHARMACEUTICAL COMPOSITION COMPRISING BROMOPHENIRAMINE, PSEUDOEPHEDRINE AND DEXTROMETHORPHAN
  申请人：WOCKHARDT LIMITED

  公开号：US20150056288A1

  公开（公告）日：2015-02-26

  There is provided a modified release liquid pharmaceutical composition comprising combination of dextromethorphan, bromrpheniramine and pseudoephedrine or pharmaceutically acceptable salts thereof. The invention further provides process for preparation of such compositions.